 |
市场调查报告书
商品编码
1567138
利伐沙班市场：按适应症、按剂型、按患者类型、按分销管道、按地区Rivaroxaban Market, By Indication (Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Prophylaxis of Venous Thromboembolism, and Others), By Formulation, By Patient Type, By Distribution Channel, By Geography |
||||||
价格
简介目录
利伐沙班的全球市场预计到2024年为1,672万美元，预计到2031年将达到2,611万美元，2024年至2031年的复合年增长率为6.6%。
| 报告范围 | 报告详情 | ||
|---|---|---|---|
| 基准年 | 2023年 | 2024年市场规模 | 1672万美元 |
| 实际资料 | 2019年至2023年 | 预测期 | 从2024年到2031年 |
| 预测 2024-2031 年复合年增长率： | 6.60% | 2031年价值预测 | 2611万美元 |
图：2024 年利伐沙班市场占有率（%），依地区划分
由于全球深层静脉栓塞症和肺动脉栓塞盛行率不断上升，利伐沙班的全球市场在过去十年中一直稳步成长。 Rivaroxaban 是一种口服抗凝血剂，可作为凝血途径中 Xa 因子的抑制剂。利伐沙班在需要抗凝血治疗的患者中用作Warfarin的抗凝血替代品。此药最常用于降低非瓣膜性心房颤动患者发生中风和全身性栓塞的风险，治疗深层静脉栓塞症和肺动脉栓塞，以及预防静脉血栓栓塞症的復发。随着人们对新型口服抗凝血剂益处的认识不断提高，以及受目标疾病影响的患者数量不断增加，利伐沙班市场预计在未来几年将继续快速扩张。
市场动态：
全球利伐沙班市场成长的驱动力是老年人口的增加，老年人口更容易发生血栓性栓塞症，相对于Warfarin等传统药物，人们对新型口服抗凝血剂的偏好日益增加，这是外科手术的增加。然而，与学名药相比，利伐沙班治疗的高昂成本是限制其广泛使用的主要因素。从积极的一面来看，临床试验正在进行中，以评估利伐沙班的其他适应症，新年龄组的核准预计将创造新的机会。此外，开发适合特定患者类型的改良剂型可能有助于克服高成本带来的挑战。
本研究的主要特点
- 本报告对全球利伐沙班市场进行了详细分析，并提出了以2023年为基准年的预测期（2024-2031）的市场规模和年复合成长率（CAGR%）。
- 它还揭示了各个细分市场的潜在商机，并说明了该市场有吸引力的投资提案矩阵。
- 它还提供了有关市场驱动因素、限制因素、机会、新产品发布和核准、市场趋势、区域前景、主要企业采取的竞争策略等的主要考察。
- 基于公司亮点、产品系列、主要亮点、财务表现和策略等参数的全球利伐沙班市场的主要企业概况。
- 该报告的见解使负责人和公司经营团队能够就未来的产品发布、类型升级、市场扩张和行销策略做出明智的决策。
- 全球利伐沙班市场报告针对该行业的各个相关人员，如投资者、供应商、产品製造商、经销商、新进业者和财务分析师。
- 透过分析全球利伐沙班市场时所使用的各种策略矩阵，将有助于相关人员做出决策。
目录
第一章 研究目的与前提
- 研究目的
- 先决条件
- 简称
第二章 市场展望
- 报告说明
- 市场定义和范围
- 执行摘要
第三章市场动态、法规与趋势分析
- 市场动态
- 影响分析
- 主要亮点
- 监管场景
- 产品发布/核准
- PEST分析
- 波特分析
- 併购场景
第四章 全球利伐沙班市场，依适应症划分，2024-2031 年（百万美元）
- 心房颤动
- 深层静脉栓塞症（DVT）
- 肺动脉栓塞（PE）
- 预防静脉血栓栓塞症（VTE）
- 其他（急性冠状动脉症候群等）
第五章全球利伐沙班市场，按剂型，2024-2031 年，（百万美元）
- 药片
- 暂停
第六章 全球利伐沙班市场，依病患类型，2024-2031 年（百万美元）
- 成人
- 小儿科
第 7 章 全球利伐沙班市场，依通路划分，2024-2031 年（百万美元）
- 医院和诊所
- 零售药房
- 网路药房
第八章全球利伐沙班市场，按地区，2019-2031，价值（百万美元）
- 北美洲
- 美国
- 加拿大
- 拉丁美洲
- 巴西
- 阿根廷
- 墨西哥
- 其他拉丁美洲
- 欧洲
- 德国
- 英国
- 西班牙
- 法国
- 义大利
- 俄罗斯
- 其他欧洲国家
- 亚太地区
- 中国
- 印度
- 日本
- 澳洲
- 韩国
- ASEAN
- 其他亚太地区
- 中东
- 海湾合作委员会国家
- 以色列
- 其他中东地区
- 非洲
- 南非
- 北非
- 中部非洲
第9章 竞争格局
- Bayer AG
- Janssen Pharmaceuticals, Inc.
- Interquim SA
- Natco Pharma
- Mylan NV
- Sandoz（a Novartis division）
- Teva Pharmaceutical Industries Ltd.
- Aurobindo Pharma
- Zydus Cadila
- Apotex Inc.
- Hetero Labs Limited
- Fresenius Kabi AG
- Sun Pharmaceutical Industries Ltd.
- Lupin Pharmaceuticals
- Reddy's Laboratories
- Bristol-Myers Squibb
- Merck & Co., Inc.
- Pfizer Inc.
- Eisai Co., Ltd.
- Amgen Inc.
第10章分析师建议
- 命运之轮
- 分析师观点
- 一致的机会图
第十一章 参考文献与调查方法
- 参考
- 调查方法
- 关于出版商
简介目录
Product Code: CMI1962
Global Rivaroxaban Market is estimated to be valued at USD 16.72 Mn in 2024 and is expected to reach USD 26.11 Mn by 2031, exhibiting a compound annual growth rate (CAGR) of 6.6% from 2024 to 2031.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2023 | Market Size in 2024: | US$ 16.72 Mn |
| Historical Data for: | 2019 To 2023 | Forecast Period: | 2024 To 2031 |
| Forecast Period 2024 to 2031 CAGR: | 6.60% | 2031 Value Projection: | US$ 26.11 Mn |
Figure. Rivaroxaban Market Share (%), By Region, 2024
The global Rivaroxaban market has been growing steadily over the past decade on the back of rising prevalence of deep vein thrombosis and pulmonary embolism disorders globally. Rivaroxaban is an oral anticoagulant that acts as an inhibitor of factor Xa in the blood coagulation pathway. It has emerged as a preferred alternative to warfarin for patients requiring anticoagulation therapy due to advantages such as fixed dosing without need for frequent monitoring. The drug is most commonly used to reduce risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation, treat deep vein thrombosis and pulmonary embolism, and reduce recurrence of venous thromboembolism. With growing awareness about benefits of novel oral anticoagulants and increasing patient pool affected by target diseases, the rivaroxaban market is anticipated to continue expanding rapidly over the coming years.
Market Dynamics:
The global rivaroxaban market growth is driven by rising geriatric population who are more prone to thromboembolic disorders, growing preference for novel oral anticoagulants over traditional drugs like warfarin, and increasing number of surgical procedures performed worldwide. However, high costs associated with rivaroxaban therapy compared to generic drugs is a major factor limiting its widespread adoption. On the positive side, ongoing clinical trials evaluating rivaroxaban for additional indications and approval for new age groups are expected to create new opportunities. Moreover, development of modified dosage forms suited for specific patient types could help overcome challenges posed by high costs.
Key features of the study:
- This report provides in-depth analysis of the global rivaroxaban market, and provides market size (USD Million) and compound annual growth rate (CAGR%) for the forecast period (2024-2031), considering 2023 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global rivaroxaban market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include Johnson & Johnson, Pfizer, Bayer, and Sanofi
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- Global rivaroxaban market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global rivaroxaban market.
Detailed Segmentation:
- By Indication Insights (Revenue, USD Mn, 2019 - 2031)
- Atrial Fibrillation
- Deep Vein Thrombosis (DVT)
- Pulmonary Embolism (PE)
- Prophylaxis of Venous Thromboembolism (VTE)
- Others (Acute Coronary Syndrome, etc.)
- By Formulation Insights (Revenue, USD Mn, 2019 - 2031)
- Tablets
- Suspension
- By Patient Type Insights (Revenue, USD Mn, 2019 - 2031)
- Adults
- Pediatrics
- By Distribution Channel Insights (Revenue, USD Mn, 2019 - 2031)
- Hospitals and Clinics
- Retail Pharmacies
- Online Pharmacies
- By Regional Insights (Revenue, USD Mn, 2019 - 2031)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players Insights
- Bayer AG
- Janssen Pharmaceuticals, Inc.
- Interquim SA
- Natco Pharma
- Mylan N.V.
- Sandoz (a Novartis division)
- Teva Pharmaceutical Industries Ltd.
- Aurobindo Pharma
- Zydus Cadila
- Apotex Inc.
- Hetero Labs Limited
- Fresenius Kabi AG
- Sun Pharmaceutical Industries Ltd.
- Lupin Pharmaceuticals
- Reddy's Laboratories
- Bristol-Myers Squibb
- Merck & Co., Inc.
- Pfizer Inc.
- Eisai Co., Ltd.
- Amgen Inc.
Table of Contents
1. RESEARCH OBJECTIVES AND ASSUMPTIONS
- Research Objectives
- Assumptions
- Abbreviations
2. MARKET PURVIEW
- Report Description
- Market Definition and Scope
- Executive Summary
- Global Rivaroxaban Market, By Indication
- Global Rivaroxaban Market, By Formulation
- Global Rivaroxaban Market, By Patient Type
- Global Rivaroxaban Market, By Distribution Channel
- Global Rivaroxaban Market, By Region
3. MARKET DYNAMICS, REGULATIONS, AND TRENDS ANALYSIS
- Market Dynamics
- Impact Analysis
- Key Highlights
- Regulatory Scenario
- Product Launches/Approvals
- PEST Analysis
- PORTER's Analysis
- Merger and Acquisition Scenario
4. Global Rivaroxaban Market, By Indication, 2024-2031, (USD Mn)
- Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
- Atrial Fibrillation
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
- Deep Vein Thrombosis (DVT)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
- Pulmonary Embolism (PE)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
- Prophylaxis of Venous Thromboembolism (VTE)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
- Others (Acute Coronary Syndrome, etc.)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
5. Global Rivaroxaban Market, By Formulation, 2024-2031, (USD Mn)
- Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2019 - 2031
- Segment Trends
- Tablets
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
- Suspension
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
6. Global Rivaroxaban Market, By Patient Type, 2024-2031, (USD Mn)
- Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2019 - 2031
- Segment Trends
- Adults
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
- Pediatrics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
7. Global Rivaroxaban Market, By Distribution Channel, 2024-2031, (USD Mn)
- Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2019 - 2031
- Segment Trends
- Hospitals and Clinics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
8. Global Rivaroxaban Market, By Region, 2019 - 2031, Value (USD Mn)
- Introduction
- Market Share (%) Analysis, 2024,2027 & 2031, Value (USD Mn)
- Market Y-o-Y Growth Analysis (%), 2019 - 2031, Value (USD Mn)
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, By Indication, 2019 - 2031, Value (USD Mn)
- Market Size and Forecast, By Formulation, 2019 - 2031, Value (USD Mn)
- Market Size and Forecast, By Patient Type, 2019 - 2031, Value (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2019 - 2031, Value (USD Mn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, By Indication, 2019 - 2031, Value (USD Mn)
- Market Size and Forecast, By Formulation, 2019 - 2031, Value (USD Mn)
- Market Size and Forecast, By Patient Type, 2019 - 2031, Value (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2019 - 2031, Value (USD Mn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, By Indication, 2019 - 2031, Value (USD Mn)
- Market Size and Forecast, By Formulation, 2019 - 2031, Value (USD Mn)
- Market Size and Forecast, By Patient Type, 2019 - 2031, Value (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2019 - 2031, Value (USD Mn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, By Indication, 2019 - 2031, Value (USD Mn)
- Market Size and Forecast, By Formulation, 2019 - 2031, Value (USD Mn)
- Market Size and Forecast, By Patient Type, 2019 - 2031, Value (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2019 - 2031, Value (USD Mn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, By Indication, 2019 - 2031, Value (USD Mn)
- Market Size and Forecast, By Formulation, 2019 - 2031, Value (USD Mn)
- Market Size and Forecast, By Patient Type, 2019 - 2031, Value (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2019 - 2031, Value (USD Mn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, By Indication, 2019 - 2031, Value (USD Mn)
- Market Size and Forecast, By Formulation, 2019 - 2031, Value (USD Mn)
- Market Size and Forecast, By Patient Type, 2019 - 2031, Value (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2019 - 2031, Value (USD Mn)
- South Africa
- North Africa
- Central Africa
9. COMPETITIVE LANDSCAPE
- Bayer AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Janssen Pharmaceuticals, Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Interquim SA
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Natco Pharma
- Mylan N.V.
- Sandoz (a Novartis division)
- Teva Pharmaceutical Industries Ltd.
- Aurobindo Pharma
- Zydus Cadila
- Apotex Inc.
- Hetero Labs Limited
- Fresenius Kabi AG
- Sun Pharmaceutical Industries Ltd.
- Lupin Pharmaceuticals
- Reddy's Laboratories
- Bristol-Myers Squibb
- Merck & Co., Inc.
- Pfizer Inc.
- Eisai Co., Ltd.
- Amgen Inc.
10. Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
11. References and Research Methodology
- References
- Research Methodology
- About us
02-2729-4219
+886-2-2729-4219
心率稳定器市场：按产品类型、用途、患者、最终用户、应用、技术 - 全球预测 2025-2030
心血管药物市场：按药物类别、适应症、患者人口统计、最终用户、给药途径、分销管道 - 2025-2030 年全球预测
盐酸阿米洛利市场：按产品类型、应用、最终用户、分销管道 - 2025-2030 年全球预测
全球心血管药物市场研究报告 - 2024 年至 2032 年产业分析、规模、份额、成长、趋势与预测
聚二甲醚市场：按配方、分销管道和用户划分 - 2024-2030 年全球预测
硫酸麻黄碱市场：依纯度、给药方式、依适应症、依地区、机会、预测，2017-2031年
心血管药物市场：按药物类型、适应症、给药途径、购买型态和最终用户划分 - 全球预测 2024-2030
血管水肿治疗药物市场：按药物类型、给药途径和最终用户划分 - 全球预测 2024-2030
心血管药物市场 - 2023-2031 年全球产业分析、规模、份额、成长、趋势与预测
全球心跳稳定器市场 - 2018-2028 年全球产业规模、份额、趋势、机会与预测，按产品类型、按应用、最终用户按地区和竞争细分
▼